Sangamo Biosciences (SGMO) AI Stock Analysis

• Market Cap: $134.77M
• Dividend Yield: N/A
• Average Volume (3M): 7.65M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: -37.13%
• EPS Growth: 40.47%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 371,684,780
• 10 Day Avg. Volume: 4,237,466
• 30 Day Avg. Volume: 7,646,780
• PEG Ratio: 0.03
• Price to Book (P/B): 9.04
• Price to Sales (P/S): 3.56
• P/FCF Ratio: -3.05
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 4.20
• Enterprise Value/Gross Profit: 4.20
• Enterprise Value/Ebitda: -1.34
• 1Y Price Target: $6.00
• Price Target Upside: 1478.95% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $0.57 ▲(50.00% Upside)
• Action: Reiterated Date: 02/04/26
• Date: Action: Reiterated 02/04/26

The score is held back primarily by weak financial performance (sharp revenue decline, ongoing losses and cash burn, and a weakened balance sheet). Offsetting this, the latest earnings call was favorable on clinical/regulatory progress for Fabry and runway extension, while technicals show above-average momentum but with overbought risk; valuation remains constrained by negative earnings and no dividend data.

Positive Factors

Regulatory Endorsement for Fabry Program

FDA endorsement of eGFR slope as an acceptable endpoint materially improves the regulatory pathway for ST-920 in Fabry disease. That reduces execution risk, supports a potential accelerated approval route, and strengthens partner and investor confidence over the medium term.

Pipeline Diversification & Platform Progress

Advancing multiple programs (neurology STAND, prion CTA preparation) demonstrates platform applicability beyond a single asset. A diversified clinical pipeline increases the probability of a value-creating outcome and makes the company a more attractive collaboration target over the next 2–6 months and beyond.

Partnership Monetization & Extended Runway

Securing a $6M partner payment and extending cash runway into Q1 2026 shows the company can monetize assets and attract industry partners. This modestly improves near-term financial flexibility and supports continued clinical progress while broader financing options are pursued.

Negative Factors

Sharp Revenue Decline and Persistent Losses

A ~60% TTM revenue decline and sustained negative margins signal deteriorating commercial traction and weak operating leverage. Over several quarters this reduces internal funding capacity, increases reliance on external financing, and constrains investment in pipeline execution and scale-up.

Weakened Balance Sheet and Higher Leverage

Debt-to-equity rising above 1.0 and a contracted equity base reduce solvency cushions and financial flexibility. Higher leverage increases refinancing risk and can limit strategic options, making the company more vulnerable to adverse clinical or funding developments over the medium term.

Negative Cash Flow and Ongoing Funding Need

Persistent negative operating and free cash flow requires repeated external financing or partnerships to sustain operations. That funding dependency risks dilution, timeline delays, or constrained program advancement if partner negotiations or capital markets access slow over the next several quarters.

Sangamo Biosciences Business Overview & Revenue Model

Company Description

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

How the Company Makes Money

Sangamo Biosciences generates revenue through a combination of partnerships, collaborations, and grants with pharmaceutical and biotechnology companies, as well as government funding. The company often enters into strategic collaborations to develop its gene therapy programs, which can include upfront payments, milestone payments based on development progress, and royalties on future product sales. Additionally, Sangamo may receive funding from research grants and public sector initiatives aimed at advancing gene-editing technologies. Its revenue model is heavily reliant on the successful development and commercialization of its therapeutic candidates, alongside leveraging its proprietary technologies for new partnerships.

Sangamo Biosciences Financial Statement Overview

Summary

Weak financial profile: TTM revenue declined sharply (~60%), profitability remains deeply negative, and operating/free cash flow are still negative despite an improvement in burn. Balance sheet flexibility has deteriorated as equity contracted and leverage increased (debt-to-equity above 1.0).

Income Statement

TTM (Trailing-Twelve-Months) revenue is down sharply (about 60% decline vs. the prior period), highlighting a weakening top-line backdrop. While gross profit is high in the most recent periods, profitability remains deeply negative: EBIT, EBITDA, and net income are all meaningfully in the red, and net margins are strongly negative across the timeline. Losses have improved versus 2023’s very large deficit, but the business is still far from breakeven and earnings quality remains a key concern.

Balance Sheet

Leverage has risen as equity has contracted materially, with debt-to-equity moving from low levels historically to above 1.0 in the most recent periods—signaling a weaker capital cushion. Total debt is not extremely large in absolute terms, but the balance sheet has less flexibility given the small equity base and continued losses (negative returns on equity). Overall, solvency risk is higher than in prior years, even if the company is not currently heavily debt-funded by nominal debt dollars.

Cash Flow

Cash generation remains pressured: operating cash flow and free cash flow are negative in TTM (Trailing-Twelve-Months) and recent annual periods, indicating ongoing cash burn. The magnitude of cash outflow has improved significantly versus 2022–2023, but the company is still consuming cash to operate. Free cash flow tracking close to net income mainly reflects that both are negative, rather than strong cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	32.88M	57.80M	176.23M	111.30M	110.70M	118.19M
Gross Profit	32.88M	57.80M	176.23M	99.19M	110.70M	-62.45M
EBITDA	-102.81M	-89.09M	-96.80M	-189.17M	-165.70M	-123.87M
Net Income	-108.91M	-97.94M	-257.83M	-192.28M	-178.29M	-121.00M
Balance Sheet
Total Assets	88.64M	101.64M	165.32M	562.51M	721.92M	938.55M
Cash, Cash Equivalents and Short-Term Investments	30.53M	41.92M	81.00M	277.63M	376.55M	641.42M
Total Debt	25.42M	30.57M	38.10M	43.11M	48.08M	42.09M
Total Liabilities	82.40M	78.86M	82.43M	267.55M	346.58M	441.18M
Stockholders Equity	6.24M	22.77M	82.89M	294.96M	375.34M	498.23M
Cash Flow
Free Cash Flow	-76.40M	-67.41M	-246.00M	-243.80M	-256.53M	155.16M
Operating Cash Flow	-76.16M	-67.14M	-224.84M	-223.63M	-233.25M	169.88M
Investing Cash Flow	1.24M	37.52M	153.53M	59.28M	248.20M	-271.63M
Financing Cash Flow	62.94M	28.38M	14.59M	84.66M	32.86M	153.10M

Sangamo Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMO, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.42, and below the 200-day MA of 0.51, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 45.93 is Neutral, neither overbought nor oversold. The STOCH value of 38.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SGMO.

Sangamo Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BDTX	59 Neutral	$128.76M	6.34	19.23%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SGMO	51 Neutral	$134.77M	-0.86	-480.02%	―	-37.13%	40.47%
CABA	50 Neutral	$301.31M	-1.24	-101.06%	―	―	-17.21%
CRBU	47 Neutral	$151.42M	-1.04	-74.28%	―	-19.00%	-2.72%
ELTX	43 Neutral	$155.31M	-2.61	―	―	―	17.36%

Sangamo Biosciences Corporate Events

Sangamo advances Fabry gene therapy with pivotal STAAR data

On February 3, 2026, Sangamo Therapeutics reported detailed clinical data from its registrational Phase 1/2 STAAR study of its Fabry disease gene therapy candidate isaralgagene civaparvovec (ST-920), covering 33 treated patients as of an April 10, 2025 cutoff and timed to presentations at the 22nd Annual WORLDSymposium in San Diego. The completed Phase 1/2 trial, in which 32 patients had at least 52 weeks of follow-up and all eligible participants rolled into a long-term extension, showed that ST-920 was generally well tolerated without preconditioning, with mostly mild to moderate adverse events, only one treatment-related serious adverse event, no thrombotic microangiopathy, no treatment-related discontinuations and no deaths. Patients demonstrated sustained normal to supraphysiological α-Gal A activity, reductions or stabilization in lyso-Gb3, and, notably, all 18 patients who entered the study on enzyme replacement therapy were able to discontinue it under supervision, while maintaining biochemical control in most cases; antibody titers against α-Gal A also decreased or became undetectable in the majority of those with baseline antibodies. Kidney function, assessed via mean annualized eGFR slope at 52 and 104 weeks, was positive and compared favorably with historical data from approved Fabry therapies, with supportive subgroup analyses, while cardiac structure and function remained stable over 52 weeks and patients showed statistically significant improvements in disease severity measures, quality of life and gastrointestinal symptoms. On the regulatory front, the U.S. FDA agreed in October 2025 that data from this Phase 1/2 STAAR study can serve as the primary basis for potential approval under the Accelerated Approval Program using 52-week eGFR slope as an intermediate endpoint, and Sangamo began a rolling Biologics License Application submission in December 2025, positioning ST-920 as a potential first gene therapy alternative to chronic enzyme replacement in Fabry disease and marking a key milestone in the company’s rare-disease gene therapy strategy.

The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.

Sangamo Biosciences Names Interim CFO After Officer Departure

On February 2, 2026, Sangamo Biosciences’ principal financial officer, Prathyusha Duraibabu, departed the company, and effective February 3, 2026, Vice President of Finance and Corporate Controller, and current principal accounting officer, Nikunj Jain, was appointed Interim Chief Financial Officer and designated as the company’s new principal financial officer. The company emphasized that Jain’s appointment involved no special arrangements, family relationships, or related-party transactions, and that he will not receive additional compensation beyond his existing pay package, underscoring a straightforward and low-disruption leadership transition in the finance function for stakeholders.

The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.